Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results